Orla Hardiman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8430766/publications.pdf

Version: 2024-02-01

397 papers	32,481 citations	5896 81 h-index	5536 163 g-index
419 all docs	419 docs citations	419 times ranked	22558 citing authors

#	Article	IF	Citations
1	Resting-state EEG reveals four subphenotypes of amyotrophic lateral sclerosis. Brain, 2022, 145, 621-631.	7.6	26
2	The patient's perspective of remote respiratory assessments during the COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 76-80.	1.7	3
3	FRONTotemporal dementia Incidence European Research Studyâ€"FRONTIERS: Rationale and design. Alzheimer's and Dementia, 2022, 18, 498-506.	0.8	12
4	Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 66-75.	1.7	1
5	Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features. Journal of Neurology, 2022, 269, 2440-2452.	3.6	28
6	Propagation patterns in motor neuron diseases: Individual and phenotype-associated disease-burden trajectories across the UMN-LMN spectrum of MNDs. Neurobiology of Aging, 2022, 109, 78-87.	3.1	17
7	Phenotypic categorisation of individual subjects with motor neuron disease based on radiological disease burden patterns: A machine-learning approach. Journal of the Neurological Sciences, 2022, 432, 120079.	0.6	25
8	Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials. Brain Imaging and Behavior, 2022, 16, 1196-1207.	2.1	7
9	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
10	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
11	Cerebellar degeneration in primary lateral sclerosis: an under-recognized facet of PLS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 542-553.	1.7	8
12	White matter microstructure alterations in frontotemporal dementia: Phenotypeâ€associated signatures and singleâ€subject interpretation. Brain and Behavior, 2022, 12, e2500.	2.2	6
13	The Latin American Epidemiology Network for ALS (Laenals). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 372-377.	1.7	5
14	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
15	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
16	A Clinical Decision Support System for the Prediction of Quality of Life in ALS. Journal of Personalized Medicine, 2022, 12, 435.	2.5	6
17	Toward a Digital Health Intervention for Vestibular Rehabilitation: Usability and Subjective Outcomes of a Novel Platform. Frontiers in Neurology, 2022, 13, 836796.	2.4	3
18	Clusters of anatomical disease-burden patterns in ALS: a data-driven approach confirms radiological subtypes. Journal of Neurology, 2022, 269, 4404-4413.	3.6	15

#	Article	IF	Citations
19	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 480-493.	10.2	124
20	Burden and benefitâ€"A mixed methods study of informal Amyotrophic Lateral Sclerosis caregivers in Ireland and the Netherlands. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	1
21	Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 465-479.	10.2	130
22	Focal thalamus pathology in frontotemporal dementia: Phenotype-associated thalamic profiles. Journal of the Neurological Sciences, 2022, 436, 120221.	0.6	12
23	Concurrent sodium channel myotonia and amyotrophic lateral sclerosis supports shared pathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A13.2-A13.	1.9	0
24	Urine concentrations of selected trace metals in a cohort of Irish adults. Environmental Science and Pollution Research, 2022, 29, 75356-75364.	5.3	2
25	Validation and standardization of the Psycholinguistic Assessments of Language Processing in Aphasia (PALPA). Aphasiology, 2021, 35, 1593-1610.	2.2	1
26	The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?. Journal of Neurology, 2021, 268, 4607-4629.	3.6	28
27	Altered supraspinal motor networks in survivors of poliomyelitis: A cortico-muscular coherence study. Clinical Neurophysiology, 2021, 132, 106-113.	1.5	7
28	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
29	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
30	Major advances in amyotrophic lateral sclerosis in 2020. Lancet Neurology, The, 2021, 20, 14-15.	10.2	8
31	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
32	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
33	The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development. Brain Imaging and Behavior, 2021, 15, 2693-2719.	2.1	15
34	Extra-motor cerebral changes and manifestations in primary lateral sclerosis. Brain Imaging and Behavior, 2021, 15, 2283-2296.	2.1	24
35	Sustained attention to response task-related beta oscillations relate to performance and provide a functional biomarker in ALS. Journal of Neural Engineering, 2021, 18, 026006.	3.5	9
36	Extra-motor manifestations in post-polio syndrome (PPS): fatigue, cognitive symptoms and radiological features. Neurological Sciences, 2021, 42, 4569-4581.	1.9	13

#	Article	IF	Citations
37	Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 460-465.	1.9	22
38	Development of an explainable clinical decision support system for the prediction of patient quality of life in amyotrophic lateral sclerosis. , 2021, , .		3
39	Discrete choice experiment for eliciting preference for health services for patients with ALS and their informal caregivers. BMC Health Services Research, 2021, 21, 213.	2.2	10
40	Development and Psychometric Evaluation of Alternate Short Forms of the Action Naming Test. Archives of Clinical Neuropsychology, 2021, , .	0.5	0
41	Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9.	1.7	0
42	Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs, 2021, 35, 483-505.	5.9	13
43	Increased cerebral integrity metrics in poliomyelitis survivors: putative adaptation to longstanding lower motor neuron degeneration. Journal of the Neurological Sciences, 2021, 424, 117361.	0.6	12
44	Infratentorial pathology in frontotemporal dementia: cerebellar grey and white matter alterations in FTD phenotypes. Journal of Neurology, 2021, 268, 4687-4697.	3.6	16
45	Prediction of caregiver quality of life in amyotrophic lateral sclerosis using explainable machine learning. Scientific Reports, 2021, 11, 12237.	3.3	13
46	Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1197-1205.	1.9	36
47	Prediction of quality of life in people with ALS. ACM SIGAPP Applied Computing Review: A Publication of the Special Interest Group on Applied Computing, 2021, 21, 5-17.	0.9	5
48	Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, 528-536.	1.1	19
49	Informal Caregivers in Amyotrophic Lateral Sclerosis: A Multi-Centre, Exploratory Study of Burden and Difficulties. Brain Sciences, 2021, 11, 1094.	2.3	15
50	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
51	Cognitive network hyperactivation and motor cortex decline correlate with ALS prognosis. Neurobiology of Aging, 2021, 104, 57-70.	3.1	13
52	A Road Map for Remote Digital Health Technology for Motor Neuron Disease. Journal of Medical Internet Research, 2021, 23, e28766.	4.3	16
53	Evaluation and categorisation of individual patients based on white matter profiles: Single-patient diffusion data interpretation in neurodegeneration. Journal of the Neurological Sciences, 2021, 428, 117584.	0.6	10
54	Correlations between measures of ALS respiratory function: is there an alternative to FVC?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 495-504.	1.7	2

#	Article	IF	Citations
55	Imaging data indicate cerebral reorganisation in poliomyelitis survivors: Possible compensation for longstanding lower motor neuron pathology. Data in Brief, 2021, 38, 107316.	1.0	3
56	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831.	10.2	9
57	Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use. Journal of Neurology, 2021, 268, 1913-1926.	3.6	15
58	SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Communications, 2021, 3, fcab236.	3.3	14
59	Imaging data reveal divergent longitudinal trajectories in PLS, ALS and poliomyelitis survivors: Group-level and single-subject traits. Data in Brief, 2021, 39, 107484.	1.0	5
60	The Experience of Amyotrophic Lateral Sclerosis in Ireland. , 2021, , 131-148.		1
61	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
62	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 33-39.	1.9	20
63	Equivalency and practice effects of alternative versions of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 86-91.	1.7	3
64	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.7	20
65	Individual quality of life in spousal ALS patient-caregiver dyads. Health and Quality of Life Outcomes, 2020, 18, 371.	2.4	24
66	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
67	Amygdala pathology in amyotrophic lateral sclerosis and primary lateral sclerosis. Journal of the Neurological Sciences, 2020, 417, 117039.	0.6	33
68	Evolving diagnostic criteria in primary lateral sclerosis: The clinical and radiological basis of â€œprobable PLSâ€• Journal of the Neurological Sciences, 2020, 417, 117052.	0.6	28
69	Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2020, 33, 649-654.	3.6	45
70	Patterns of Language Impairment in Early ALS. Neurology: Clinical Practice, 2020, 11, 10.1212/CPJ.0000000000001006.	1.6	5
71	MRI data confirm the selective involvement of thalamic and amygdalar nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. Data in Brief, 2020, 32, 106246.	1.0	15
72	Imaging and clinical data indicate considerable disease burden in â€˜probableâ€™ PLS: Patients with UMN symptoms for 2â€“4 years. Data in Brief, 2020, 32, 106247.	1.0	10

#	Article	IF	Citations
73	Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 355-363.	1.7	27
74	â€œSwitchboardâ€•malfunction in motor neuron diseases: Selective pathology of thalamic nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. NeuroImage: Clinical, 2020, 27, 102300.	2.7	45
75	The reading the mind in the eyes test short form (A & B): validation and outcomes in an amyotrophic lateral sclerosis cohort. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 380-388.	1.7	9
76	Generation of twelve induced pluripotent stem cell lines from two healthy controls and two patients with sporadic amyotrophic lateral sclerosis. Stem Cell Research, 2020, 44, 101752.	0.7	2
77	Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland. Frontiers in Neurology, 2020, 11, 527.	2.4	17
78	The Beginning of Genomic Therapies for ALS. New England Journal of Medicine, 2020, 383, 180-181.	27.0	12
79	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
80	Concurrent sodium channelopathies and amyotrophic lateral sclerosis supports shared pathogenesis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 627-630.	1.7	5
81	Connectomeâ€Based Propagation Model in Amyotrophic Lateral Sclerosis. Annals of Neurology, 2020, 87, 725-738.	5.3	51
82	Progressive brainstem pathology in motor neuron diseases: Imaging data from amyotrophic lateral sclerosis and primary lateral sclerosis. Data in Brief, 2020, 29, 105229.	1.0	16
83	Thalamic, hippocampal and basal ganglia pathology in primary lateral sclerosis and amyotrophic lateral sclerosis: Evidence from quantitative imaging data. Data in Brief, 2020, 29, 105115.	1.0	17
84	Prediction of caregiver burden in amyotrophic lateral sclerosis: a machine learning approach using random forests applied to a cohort study. BMJ Open, 2020, 10, e033109.	1.9	16
85	Localization of Brain Networks Engaged by the Sustained Attention to Response Task Provides Quantitative Markers of Executive Impairment in Amyotrophic Lateral Sclerosis. Cerebral Cortex, 2020, 30, 4834-4846.	2.9	10
86	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	1.5	268
87	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
88	Cross-reactive probes on Illumina DNA methylation arrays: a large study on ALS shows that a cautionary approach is warranted in interpreting epigenome-wide association studies. NAR Genomics and Bioinformatics, 2020, 2, lqaa105.	3.2	13
89	Identifying Features That Are Predictive of Quality of Life in People With Amyotrophic Lateral Sclerosis. , 2020, , .		4
90	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 11-19.	1.9	26

#	Article	IF	Citations
91	Post-polio Syndrome: More Than Just a Lower Motor Neuron Disease. Frontiers in Neurology, 2019, 10, 773.	2.4	59
92	The clinical and radiological profile of primary lateral sclerosis: a population-based study. Journal of Neurology, 2019, 266, 2718-2733.	3.6	58
93	Longitudinal analysis of sniff nasal inspiratory pressure assessed using occluded and un-occluded measurement techniques in amyotrophic lateral sclerosis and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 481-489.	1.7	10
94	Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2019, 76, 1367.	9.0	130
95	Patterned functional network disruption in amyotrophic lateral sclerosis. Human Brain Mapping, 2019, 40, 4827-4842.	3.6	65
96	Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: A longitudinal neuroimaging study. NeuroImage: Clinical, 2019, 24, 102054.	2.7	59
97	Associations of Electric Shock and Extremely Low-Frequency Magnetic Field Exposure With the Risk of Amyotrophic Lateral Sclerosis. American Journal of Epidemiology, 2019, 188, 796-805.	3.4	20
98	Generation of six induced pluripotent stem cell (iPSC) lines from two patients with amyotrophic lateral sclerosis (NUIGi043-A, NUIGi043-B, NUIGi043-C, NUIGi044-A, NUIGi044-B, NUIGi044-C). Stem Cell Research, 2019, 40, 101558.	0.7	4
99	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Scientific Reports, 2019, 9, 690.	3.3	46
100	A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 584-594.	1.7	29
101	Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 659-665.	1.9	18
102	Multicentre, population-based, caseâ€“control study of particulates, combustion products and amyotrophic lateral sclerosis risk. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 854-860.	1.9	17
103	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 5931.	3.3	16
104	Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention. Frontiers in Neurology, 2019, 10, 260.	2.4	40
105	Two heads are better than one: benefits of joint models for ALS trials. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1071-1072.	1.9	6
106	Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS. Frontiers in Neurology, 2019, 10, 229.	2.4	67
107	Building a supportive framework for brain research in Ireland: Inaugural position paper of the Irish Brain Council. European Journal of Neuroscience, 2019, 49, 1362-1370.	2.6	0
108	Neurophysiological markers of network dysfunction in neurodegenerative diseases. NeuroImage: Clinical, 2019, 22, 101706.	2.7	27

#	Article	IF	Citations
109	Dysfunction of attention switching networks in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2019, 22, 101707.	2.7	18
110	Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1011-1020.	1.9	45
111	Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. Cell Reports, 2019, 26, 2298-2306.e5.	6.4	57
112	Group interventions for amyotrophic lateral sclerosis caregivers in Ireland: a randomised controlled trial protocol. BMJ Open, 2019, 9, e030684.	1.9	10
113	Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1165-1170.	1.9	17
114	Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Science Translational Medicine, 2019, 11, .	12.4	37
115	Widespread subcortical grey matter degeneration in primary lateral sclerosis: a multimodal imaging study with genetic profiling. NeuroImage: Clinical, 2019, 24, 102089.	2.7	60
116	Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 133-145.	1.7	69
117	Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. Neurobiology of Aging, 2019, 74, 234.e9-234.e15.	3.1	26
118	Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis. Cerebral Cortex, 2019, 29, 27-41.	2.9	76
119	The C9orf72 expansion is associated with accelerated respiratory function decline in a large Amyotrophic Lateral Sclerosis cohort. HRB Open Research, 2019, 2, 23.	0.6	7
120	Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 331-341.	1.7	31
121	Multicentre, cross-cultural, population-based, caseâ€“control study of physical activity as risk factor for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 797-803.	1.9	45
122	Needs of informal caregivers across the caregiving course in amyotrophic lateral sclerosis: a qualitative analysis. BMJ Open, 2018, 8, e018721.	1.9	37
123	ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 57-64.	1.7	19
124	VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 259-266.	1.7	21
125	Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patientâ€“caregiver dyads. Journal of Neurology, 2018, 265, 793-808.	3.6	28
126	Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging and Behavior, 2018, 12, 1696-1707.	2.1	89

#	Article	IF	Citations
127	The Study of Language in the Amyotrophic Lateral Sclerosis - Frontotemporal Spectrum Disorder: a Systematic Review of Findings and New Perspectives. Neuropsychology Review, 2018, 28, 251-268.	4.9	40
128	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
129	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
130	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
131	Respiratory measures in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 321-330.	1.7	44
132	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
133	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.7	26
134	Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 232-241.	1.7	82
135	Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 65-73.	1.7	28
136	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
137	Global burden of motor neuron diseases: mind the gaps. Lancet Neurology, The, 2018, 17, 1030-1031.	10.2	5
138	ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology, 2018, 91, e1370-e1380.	1.1	170
139	Determining the incidence of familiality in ALS. Neurology: Genetics, 2018, 4, e239.	1.9	27
140	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiology of Aging, 2018, 71, 266.e1-266.e10.	3.1	59
141	Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821.	2.5	22
142	Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. European Journal of Human Genetics, 2018, 26, 1537-1546.	2.8	129
143	The multistep hypothesis of ALS revisited. Neurology, 2018, 91, e635-e642.	1.1	146
144	The life expectancy of Stephen Hawking, according to the ENCALS model. Lancet Neurology, The, 2018, 17, 662-663.	10.2	6

#	Article	IF	Citations
145	Insular Celtic population structure and genomic footprints of migration. PLoS Genetics, 2018, 14, e1007152.	3.5	30
146	Genetic testing in ALS. Neurology, 2017, 88, 991-999.	1.1	57
147	Visual encoding, consolidation, and retrieval in amyotrophic lateral sclerosis: executive function as a mediator, and predictor of performance. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 193-201.	1.7	17
148	What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 381-385.	1.9	88
149	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.1-281.	1.9	33
150	Atypical social cognitive processing in premotor Huntingtonâ€™s disease: a single case study. Irish Journal of Psychological Medicine, 2017, 34, 53-58.	1.0	1
151	Caregivers of patients with amyotrophic lateral sclerosis: investigating quality of life, caregiver burden, service engagement, and patient survival. Journal of Neurology, 2017, 264, 898-904.	3.6	35
152	The changing picture of amyotrophic lateral sclerosis: lessons from European registers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 557-563.	1.9	89
153	ALSUntangled No. 37: Inosine*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 309-312.	1.7	1
154	Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurology, 2017, 17, 73.	1.8	71
155	A Crossâ€sectional populationâ€based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Annals of Clinical and Translational Neurology, 2017, 4, 305-317.	3.7	63
156	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	129
157	Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 68-73.	1.7	64
158	ALSUntangled 38: L-serine. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 148-151.	1.7	3
159	Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease. Neurology, 2017, 88, 2321-2329.	1.1	48
160	Edaravone: a new treatment for ALS on the horizon?. Lancet Neurology, The, 2017, 16, 490-491.	10.2	61
161	Amyotrophic lateral sclerosis. Lancet, The, 2017, 390, 2084-2098.	13.7	867
162	Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 611-623.	1.7	63

#	Article	IF	Citations
163	Virtual brain biopsies in amyotrophic lateral sclerosis: Diagnostic classification based on in vivo pathological patterns. NeuroImage: Clinical, 2017, 15, 653-658.	2.7	66
164	Assessing behavioural changes in ALS: cross-validation of ALS-specific measures. Journal of Neurology, 2017, 264, 1397-1401.	3.6	10
165	From first symptoms to diagnosis of amyotrophic lateral sclerosis: perspectives of an Irish informal caregiver cohortâ€"a thematic analysis. BMJ Open, 2017, 7, e014985.	1.9	26
166	Genetic effects influencing risk for major depressive disorder in China and Europe. Translational Psychiatry, 2017, 7, e1074-e1074.	4.8	64
167	Critical issues in ALS case-control studies: the case of the Euro-MOTOR study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 411-418.	1.7	16
168	Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 2017, 8, 14774.	12.8	114
169	Screening for cognitive dysfunction in ALS: validation of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative data. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 99-106.	1.7	63
170	A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology, 2017, 88, 304-313.	1.1	79
171	A genetic overview of Atlantic coastal populations from Europe and North-West Africa based on a 17 X-STR panel. Forensic Science International: Genetics, 2017, 27, 167-171.	3.1	9
172	The beginning of precision medicine in ALS?. Neurology, 2017, 89, 1850-1851.	1.1	5
173	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	30.5	885
174	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
175	Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 1425.	9.0	52
176	A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology, 2017, 89, 1283-1290.	1.1	48
177	Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Research, 2017, 27, 1895-1903.	5.5	277
178	ALSUntangled No. 36: Accilion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 142-147.	1.7	1
179	Genetic screening in sporadic ALS and FTD. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1042-1044.	1.9	105
180	Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Molecular Brain, 2017, 10, 22.	2.6	101

#	Article	IF	Citations
181	The effects of a home-based arm ergometry exercise programme on physical fitness, fatigue and activity in Polio survivors: a randomised controlled trial. Clinical Rehabilitation, 2017, 31, 913-925.	2.2	6
182	Estimation of coherence using the median is robust against EEG artefacts. , 2017, 2017, 3949-3952.		16
183	Mismatch Negativity as an Indicator of Cognitive Sub-Domain Dysfunction in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2017, 8, 395.	2.4	24
184	Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype. Frontiers in Molecular Neuroscience, 2017, 10, 370.	2.9	24
185	The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population- based study of consultations, interventions and costs. PLoS ONE, 2017, 12, e0179796.	2.5	48
186	From pneumomyelography to cord tractography: historical perspectives on spinal imaging. Future Neurology, 2017, 12, 121-124.	0.5	2
187	Measurement of Social Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study. PLoS ONE, 2016, 11, e0160850.	2.5	63
188	Age-period-cohort analysis of trends in amyotrophic lateral sclerosis incidence. Journal of Neurology, 2016, 263, 1919-1926.	3.6	18
189	The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration. European Journal of Neurology, 2016, 23, 1361-1371.	3.3	63
190	Survival analysis of geospatial factors in the Irish ALS cohort. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 555-560.	1.7	5
191	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 325-336.	1.7	14
192	Palliative Care and End of Life Care. , 2016, , 305-319.		2
193	The selective anatomical vulnerability of ALS: â€˜disease-definingâ€™ and â€˜disease-defyingâ€™ brain regions. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 561-570.	1.7	57
194	Discordant performance on the â€˜Reading the Mind in the Eyesâ€™ Test, based on disease onset in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 467-472.	1.7	46
195	Caregiving in ALS â€“ a mixed methods approach to the study of Burden. BMC Palliative Care, 2016, 15, 81.	1.8	79
196	Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurology, The, 2016, 15, 1182-1194.	10.2	301
197	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
198	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218

#	Article	IF	Citations
199	ALSUntangled No. 34: GM604. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 617-621.	1.7	1
200	ALSUntangled No. 35: Hyperbaric Oxygen Therapy*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 622-624.	1.7	0
201	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	12.8	174
202	Association of a Locus in theCAMTA1Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
203	Genomic signals of migration and continuity in Britain before the Anglo-Saxons. Nature Communications, 2016, 7, 10326.	12.8	100
204	Common Themes in the Pathogenesis of Neurodegeneration. , 2016, , 1-12.		4
205	No association between soil constituents and amyotrophic lateral sclerosis relative risk in Ireland. Environmental Research, 2016, 147, 102-107.	7.5	10
206	â€œI hate being a burdenâ€• The patient perspective on carer burden in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 351-357.	1.7	26
207	New clues to the evolutionary history of the main European paternal lineage M269: dissection of the Y-SNP S116 in Atlantic Europe and Iberia. European Journal of Human Genetics, 2016, 24, 437-441.	2.8	26
208	Development of an Automated MRI-Based Diagnostic Protocol for Amyotrophic Lateral Sclerosis Using Disease-Specific Pathognomonic Features: A Quantitative Disease-State Classification Study. PLoS ONE, 2016, 11, e0167331.	2.5	65
209	Medical Mimics of Neurodegenerative Diseases. , 2016, , 199-212.		0
210	Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study. BMC Health Services Research, 2015, 15, 571.	2.2	30
211	Genetics of ALS. , 2015, , 385-409.		0
212	Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 857.	9.0	29
213	Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors. Journal of Neurology, 2015, 262, 1526-1532.	3.6	85
214	Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland. Neurology, 2015, 85, 1822-1823.	1.1	3
215	Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland. Neurology, 2015, 84, 1537-1544.	1.1	23
216	A novel MYH7 Leu1453pro mutation resulting in Laing distal myopathy in an Irish family. Neuromuscular Disorders, 2015, 25, 155-160.	0.6	9

#	Article	IF	Citations
217	A second-generation Irish genome-wide association study for amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 1221.e7-1221.e13.	3.1	10
218	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science, 2015, 347, 1436-1441.	12.6	823
219	Presymptomatic and longitudinal neuroimaging in neurodegenerationâ€"from snapshots to motion picture: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1089-1096.	1.9	78
220	The El Escorial criteria: Strengths and weaknesses. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 1-7.	1.7	69
221	Health and social care costs of managing amyotrophic lateral sclerosis (ALS): An Irish perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 58-62.	1.7	18
222	ALSUntangled: Introducing The Table of Evidence. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 142-145.	1.7	10
223	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nature Biotechnology, 2015, 33, 51-57.	17.5	178
224	A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 496-501.	1.9	170
225	A revision of the El Escorial criteria - 2015. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 291-292.	1.7	373
226	ALSUntangled No. 29: MitoQ. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 427-429.	1.7	1
227	Homozygosity mapping in an Irish ALS caseâ€"control cohort describes local demographic phenomena and points towards potential recessive risk loci. Genomics, 2015, 105, 237-241.	2.9	15
228	Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of Neurology, 2015, 262, 1447-1454.	3.6	84
229	End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 435-442.	10.2	154
230	Social deprivation and population density are not associated with small area risk of amyotrophic lateral sclerosis. Environmental Research, 2015, 142, 141-147.	7.5	10
231	Ataxin-2 expands insight into the ALS clinical spectrum. Neurology, 2015, 84, 224-225.	1.1	0
232	Patterns of cerebral and cerebellar white matter degeneration in ALS: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 468-470.	1.9	58
233	First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. Neuropharmacology, 2015, 89, 193-203.	4.1	18
234	Functional Connectivity Changes in Resting-State EEG as Potential Biomarker for Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0128682.	2.5	51

#	Article	IF	Citations
235	An Exploratory Spatial Analysis of ALS Incidence in Ireland over 17.5 Years (1995 â€“ July 2013). PLoS ONE, 2014, 9, e96556.	2.5	11
236	Assessment of subjective and motor fatigue in Polio survivors, attending a Postpolio clinic, comparison with healthy controls and an exploration of clinical correlates. Physiotherapy Theory and Practice, 2014, 30, 229-235.	1.3	10
237	Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 148-150.	1.7	48
238	Fecundity in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 204-206.	1.7	5
239	Sexual dimorphism in ALS: Exploring gender-specific neuroimaging signatures. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 235-243.	1.7	53
240	Retrospective investigations of practice effects on repeated neuropsychological measures of executive functioning. Irish Journal of Psychology, 2014, 35, 178-187.	0.2	6
241	Understanding psycho-social processes underpinning engagement with services in motor neurone disease: A qualitative study. Palliative Medicine, 2014, 28, 318-325.	3.1	35
242	Andersenâ€“Tawil Syndrome With Early Fixed Myopathy. Journal of Clinical Neuromuscular Disease, 2014, 16, 79-82.	0.7	10
243	Acceptance and Decision Making in Amyotrophic Lateral Sclerosis From a Life-Course Perspective. Qualitative Health Research, 2014, 24, 67-77.	2.1	28
244	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
245	â€œSand-watchâ€•spinal cord: a case of inferior cervical spinal cord atrophy. Journal of Neurology, 2014, 261, 235-237.	3.6	12
246	Exerting control and adapting to loss in amyotrophic lateral sclerosis. Social Science and Medicine, 2014, 101, 113-119.	3.8	52
247	Lessons of ALS imaging: Pitfalls and future directions â€” A critical review. NeuroImage: Clinical, 2014, 4, 436-443.	2.7	98
248	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 2220-2231.	2.9	123
249	ALSUntangled No. 26: Lunasin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 622-626.	1.7	7
250	Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurology, The, 2014, 13, 1108-1113.	10.2	302
251	Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. Neuron, 2014, 84, 324-331.	8.1	308
252	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 1916-1922.	2.9	23

#	Article	IF	Citations
253	Physical activity and amyotrophic lateral sclerosis: A European populationâ€based caseâ€“control study. Annals of Neurology, 2014, 75, 708-716.	5.3	79
254	<scp>C9orf72</scp> and <scp>UNC13A</scp> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genomeâ€wide metaâ€analysis. Annals of Neurology, 2014, 76, 120-133.	5.3	91
255	Analysis of the hexanucleotide repeat expansion and founder haplotype at C9ORF72 in an Irish psychosis case-control sample. Neurobiology of Aging, 2014, 35, 1510.e1-1510.e5.	3.1	20
256	UBQLN2 mutations are not a frequent cause of amyotrophic lateral sclerosis in Ireland. Neurobiology of Aging, 2014, 35, 267.e9-267.e11.	3.1	8
257	Subcortical gray matter structures: a future biomarker for amyotrophic lateral sclerosis?. Future Neurology, 2014, 9, 109-111.	0.5	0
258	Methodology and Design of a National Epidemiological Study on Adult Neuromuscular Disease. Neuroepidemiology, 2014, 43, 123-130.	2.3	5
259	Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology, The, 2013, 12, 1059-1067.	10.2	216
260	The epidemiology of ALS: a conspiracy of genes, environment and time. Nature Reviews Neurology, 2013, 9, 617-628.	10.1	658
261	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
262	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiology of Aging, 2013, 34, 357.e7-357.e19.	3.1	69
263	H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiology of Aging, 2013, 34, 1517.e5-1517.e7.	3.1	19
264	Using Reference Databases of Genetic Variation to Evaluate the Potential Pathogenicity of Candidate Disease Variants. Human Mutation, 2013, 34, 836-841.	2.5	30
265	Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 766-773.	1.9	121
266	Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology, 2013, 81, 361-369.	1.1	150
267	Blink rate in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 291-293.	1.7	8
268	Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 33-43.	1.7	33
269	Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology, 2013, 81, 2107-2115.	1.1	147
270	Cognitive changes predict functional decline in ALS. Neurology, 2013, 80, 1590-1597.	1.1	237

#	Article	IF	Citations
271	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
272	Age at onset of amyotrophic lateral sclerosis is proportional to life expectancy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 604-607.	1.7	14
273	Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A populationâ€based caseâ€“control cohort study of familial and sporadic amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 699-708.	5.3	116
274	Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. Journal of Medical Genetics, 2013, 50, 776-783.	3.2	151
275	Survival Analysis of Irish Amyotrophic Lateral Sclerosis Patients Diagnosed from 1995â€“2010. PLoS ONE, 2013, 8, e74733.	2.5	67
276	ALS Untangled No. 17: â€œWhen ALS Is Lymeâ€• Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 487-491.	2.1	6
277	Spinal cord markers in ALS: Diagnostic and biomarker considerations. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 407-415.	2.1	50
278	Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 365-367.	1.9	65
279	Experience of Services as a Key Outcome in Amyotrophic Lateral Sclerosis (ALS) Care. American Journal of Hospice and Palliative Medicine, 2012, 29, 362-367.	1.4	18
280	Ask the Experts: Translating amyotrophic lateral sclerosis genetics to the clinic: implications for the patient. Neurodegenerative Disease Management, 2012, 2, 355-360.	2.2	0
281	The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 102-108.	1.9	557
282	Patientsâ€™ perceptions of services and preferences for care in amyotrophic lateral sclerosis: A review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 11-24.	2.1	50
283	ALSUntangled No. 16: Cannabis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 400-404.	2.1	9
284	ALSUntangled 15: Coconut Oil. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 328-330.	2.1	6
285	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nature Medicine, 2012, 18, 1418-1422.	30.7	269
286	Social cognition in neurodegenerative disorders: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1071-1079.	1.9	91
287	The effects of a home-based arm ergometry exercise programme on physical fitness, fatigue and activity in polio survivors: protocol for a randomised controlled trial. BMC Neurology, 2012, 12, 157.	1.8	5
288	Multidisciplinary Care in ALS: Expanding the Team. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 165-165.	2.1	9

#	Article	IF	Citations
289	Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for Sporadic ALS. PLoS ONE, 2012, 7, e35333.	2.5	50
290	The expansions of ALS. Neurology, 2012, 79, 842-843.	1.1	1
291	Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurology, The, 2012, 11, 232-240.	10.2	493
292	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) â€“ revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
293	Trauma and amyotrophic lateral sclerosis: a caseâ€“control study from a populationâ€based registry. European Journal of Neurology, 2012, 19, 1509-1517.	3.3	63
294	Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 413-418.	1.9	95
295	Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews Neurology, 2011, 7, 639-649.	10.1	503
296	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Progress in Neurobiology, 2011, 95, 649-662.	5.7	47
297	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10.	2.1	107
298	Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology, 2011, 76, 1263-1269.	1.1	324
299	Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955.	13.7	2,182
300	Management of respiratory symptoms in ALS. Journal of Neurology, 2011, 258, 359-365.	3.6	64
301	Waterskierâ€™s Hirayama syndrome. Journal of Neurology, 2011, 258, 2078-2079.	3.6	10
302	Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. British Journal of Psychiatry, 2011, 199, 508-509.	2.8	94
303	Amyotrophic lateral sclerosis and vascular risk: a metabolic conundrum. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 591-591.	1.9	3
304	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	3.4	50
305	Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 623-627.	1.9	283
306	Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. BMJ Supportive and Palliative Care, 2011, 1, 343-348.	1.6	14

#	Article	IF	Citations
307	Proposed criteria for familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 157-159.	2.1	120
308	Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 385-390.	1.9	648
309	Slow saccades in bulbar-onset motor neurone disease. Journal of Neurology, 2010, 257, 1134-1140.	3.6	43
310	Validating population-based registers for ALS: how accurate is death certification?. Journal of Neurology, 2010, 257, 1235-1239.	3.6	25
311	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology, The, 2010, 9, 986-994.	10.2	205
312	Familial aggregation in amyotrophic lateral sclerosis. Annals of Neurology, 2010, 67, 554-554.	5.3	7
313	A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Human Molecular Genetics, 2010, 19, 4091-4099.	2.9	51
314	Willful Modulation of Brain Activity in Disorders of Consciousness. New England Journal of Medicine, 2010, 362, 1936-1938.	27.0	5
315	Amyotrophic lateral sclerosis, physical exercise, trauma and sports: Results of a population-based pilot case-control study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 289-292.	2.1	110
316	Sequencing and analysis of an Irish human genome. Genome Biology, 2010, 11, R91.	9.6	36
317	Measuring life quality, physical function and psychological well-being in neurological illness. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 461-468.	2.1	23
318	The epidemiology of motor neuron disease in Northern Ireland using capture-recapture methodology. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 374-378.	2.1	27
319	Huntington's disease presenting as amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 405-407.	2.1	7
320	Huntington's disease presenting as amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 1-3.	2.1	7
321	Angiogenin Levels and ANG Genotypes: Dysregulation in Amyotrophic Lateral Sclerosis. PLoS ONE, 2010, 5, e15402.	2.5	21
322	Geographical structure and differential natural selection among North European populations. Genome Research, 2009, 19, 804-814.	5.5	75
323	Aggregation of neurodegenerative disease in ALS kindreds. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 95-98.	2.1	41
324	ALSUntangled (ALSU): A Scientific Approach to Off-Label Treatment Options for People with ALS Using Tweets and Twitters. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 129-130.	2.1	22

#	Article	IF	Citations
325	Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9004-9009.	7.1	177
326	Ocular fixation instabilities in motor neurone disease. Journal of Neurology, 2009, 256, 420-426.	3.6	48
327	The management of amyotrophic lateral sclerosis. Journal of Neurology, 2009, 256, 176-186.	3.6	40
328	Screening for replication of genome-wide SNP associations in sporadic ALS. European Journal of Human Genetics, 2009, 17, 213-218.	2.8	57
329	Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nature Genetics, 2009, 41, 1083-1087.	21.4	344
330	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 310-323.	2.1	839
331	A case of stiff-person syndrome, type 1 diabetes, celiac disease and dermatitis herpetiformis. Clinical Neurology and Neurosurgery, 2009, 111, 384-386.	1.4	13
332	High Incidence of Osteoporosis and Fractures in an Aging Post-Polio Population. European Neurology, 2009, 62, 369-374.	1.4	51
333	Analysis ofFGGYas a risk factor for sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 441-447.	2.1	15
334	Ten years of the ALS journal. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 257-257.	2.1	0
335	Amyotrophic lateral sclerosis and soccer: A different epidemiological approach strengthen the previous findings. Journal of the Neurological Sciences, 2008, 269, 187-188.	0.6	12
336	Evaluation of the Golgi trafficking protein VPS54 (wobbler) as a candidate for ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 141-148.	2.1	31
337	A new editor for the â€œBlack but not bleakâ€•journal â€“ ALS research is coming of age. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 3-3.	2.1	0
338	Screening of hypoxia-inducible genes in sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 299-305.	2.1	2
339	Analysis of genome-wide copy number variation in Irish and Dutch ALS populations. Human Molecular Genetics, 2008, 17, 3392-3398.	2.9	41
340	Control of Motoneuron Survival by Angiogenin. Journal of Neuroscience, 2008, 28, 14056-14061.	3.6	154
341	Boosting controlled autoimmunity: a new therapeutic target for CNS disorders. Expert Review of Neurotherapeutics, 2008, 8, 819-825.	2.8	3
342	50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 229-237.	2.1	29

#	Article	IF	Citations
343	Timeliness of diagnosis in motor neurone disease: a population-based study. Ulster Medical Journal, 2008, 77, 18-21.	0.2	11
344	Perceptions of quality of life in people with ALS: Effects of coping and health care. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 164-169.	2.1	34
345	Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 984-986.	1.9	54
346	A genome-wide association study of sporadic ALS in a homogenous Irish population. Human Molecular Genetics, 2007, 17, 768-774.	2.9	182
347	ETHNIC VARIATION IN THE INCIDENCE OF ALS: A SYSTEMATIC REVIEW. Neurology, 2007, 69, 711-712.	1.1	4
348	Quantitative assessment of motor fatigue: Normative values and comparison with priorâ€polio patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 170-176.	2.1	16
349	The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. Current Medicinal Chemistry, 2007, 14, 3185-3200.	2.4	62
350	Phase II/III randomized trial of TCH346 in patients with ALS. Neurology, 2007, 69, 776-784.	1.1	112
351	Ethnic variation in the incidence of ALS. Neurology, 2007, 68, 1002-1007.	1.1	236
352	Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Hormone and IGF Research, 2007, 17, 472-479.	1.1	40
353	Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidenceâ€based review with good practice points. EALSC Working Group. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 195-213.	2.1	168
354	Maximum voluntary isometric contraction: Reference values and clinical application. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 47-55.	2.1	89
355	The complex genetics of amyotrophic lateral sclerosis. Lancet Neurology, The, 2007, 6, 291-292.	10.2	8
356	Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurology, The, 2007, 6, 994-1003.	10.2	566
357	The epidemiology of ALS and the role of population-based registries. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1150-1157.	3.8	168
358	Sonographically Guided Percutaneous Muscle Biopsy in Diagnosis of Neuromuscular Disease. Journal of Ultrasound in Medicine, 2006, 25, 1-6.	1.7	35
359	ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genetics, 2006, 38, 411-413.	21.4	617
360	A 45-year history of acquired autoimmune neuromyotonia. Journal of Neurology, 2006, 253, 1243-1245.	3.6	1

#	Article	IF	Citations
361	Analysis of IFT74as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurology, 2006, 6, 44.	1.8	70
362	EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. An evidence-based review with good practice points. European Journal of Neurology, 2005, 12, 921-938.	3.3	261
363	Use of Sniff Nasal-Inspiratory Force to Predict Survival in Amyotrophic Lateral Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 269-274.	5.6	215
364	Physical decline and quality of life in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 230-234.	1.2	22
365	Recovery of the upper limb post ischaemic stroke and the predictive value of the Orpington Prognostic Score. Clinical Rehabilitation, 2004, 18, 694-702.	2.2	23
366	Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 150-153.	1.2	27
367	Buspirone Challenge is not a valid Probe of Central 5-HT1A Receptor Function. Cephalalgia, 2004, 24, 510-511.	3.9	1
368	An outcome study of riluzole in amyotrophic lateral sclerosis. Journal of Neurology, 2003, 250, 473-479.	3.6	128
369	Factors Associated With Burden of Primary Headache in a Specialty Clinic. Headache, 2003, 43, 638-644.	3.9	53
370	Differing central amine receptor sensitivity in different migraine subtypes? A neuroendocrine study using buspirone. Pain, 2003, 101, 283-290.	4.2	12
371	The Oxfordshire Community Stroke Project classification: Correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 1-7.	1.6	79
372	The orpington prognostic scale within the first 48 hours of admission as a predictor of outcome in ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 175-181.	1.6	8
373	Maximum Voluntary Isometric Contraction: Investigation of Reliability and Learning Effect. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 36-44.	1.2	32
374	A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport^{Â®}) in the Treatment of Spastic Equinovarus Deformity after Stroke. Cerebrovascular Diseases, 2003, 15, 289-300.	1.7	186
375	Polymyositis Masquerading as Motor Neuron Disease. Archives of Neurology, 2003, 60, 1001.	4.5	11
376	Maximum Voluntary Isometric Contraction: Investigation of Reliability and Learning Effect. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 36-44.	1.2	0
377	Factors which predict physical and mental health status in patients with amyotrophic lateral sclerosis over time. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 112-117.	1.2	0
378	Models of care for motor neuron disease: setting standards. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 182-185.	1.2	22

#	Article	IF	Citations
379	Amyotrophic Lateral Sclerosis: Enteral Nutrition Provisionâ€"Endoscopic or Radiologic Gastrostomy?. Radiology, 2002, 224, 713-717.	7.3	124
380	The "Spray Can" Sign. Archives of Neurology, 2002, 59, 1637.	4.5	0
381	?True? sporadic ALS associated with a novel SOD-1 mutation. Annals of Neurology, 2002, 52, 680-683.	5.3	98
382	Assessing individual quality of life in amyotrophic lateral sclerosis. Quality of Life Research, 2001, 10, 149-158.	3.1	98
383	Rapid-onset dystonia-parkinsonism. Neurology, 2000, 55, 991-995.	1.1	139
384	Pitfalls in the diagnosis of motor neurone disease. British Journal of Hospital Medicine, 2000, 61, 767-771.	0.2	6
385	Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis. Journal of Neurology, 2000, 247, 245-251.	3.6	64
386	Amyotrophic Lateral Sclerosis Mimic Syndromes. Archives of Neurology, 2000, 57, 109.	4.5	205
387	Clinical Features of Amyotrophic Lateral Sclerosis According to the El Escorial and Airlie House Diagnostic Criteria. Archives of Neurology, 2000, 57, 1171.	4.5	403
388	Binding of 125I-insulin-like growth factor-II to cells cultured in fetal bovine serum: a complication. International Journal of Biochemistry and Cell Biology, 2000, 32, 189-200.	2.8	1
389	National scientific medical meeting 1997 abstracts. Irish Journal of Medical Science, 1998, 167, 1-44.	1.5	0
390	Status Epilepticus. New England Journal of Medicine, 1998, 339, 409-410.	27.0	9
391	Irish neurological association. Irish Journal of Medical Science, 1993, 162, 474-484.	1.5	0
392	Neuropathic Findings in Oculopharyngeal Muscular Dystrophy. Archives of Neurology, 1993, 50, 481.	4.5	26
393	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1992, 161, 639-652.	1.5	0
394	Interictal spiking and seizures. Annals of Neurology, 1986, 19, 609-610.	5.3	0
395	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-14.	2.1	16
396	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4

#	Article	IF	Citations
397	Mutations in the Glycosyltransferase Domain of GLT8D1 Cause Amyotrophic Lateral Sclerosis. SSRN Electronic Journal, 0, , .	0.4	0